# Haemonetics Corp (HAE)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/haemonetics-corp/ JSON: https://steadybase.io/company/haemonetics-corp.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: HAEMONETICS CORP
- Ticker: HAE (NYSE)
- SEC CIK: 0000313143
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Boston, MA
- Fiscal year ends: April 3
- SEC filer category: Large accelerated filer
- Website: haemonetics.com
- LinkedIn: https://www.linkedin.com/company/haemonetics
- Next earnings date: Feb 4, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $1.3B for the fiscal year ended Mar 28, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/0000313143-26-000050-index.html
- Operating income: $156.7M for the fiscal year ended Mar 28, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/0000313143-26-000050-index.html
- Net income: $97.3M for the fiscal year ended Mar 28, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/0000313143-26-000050-index.html
- SG&A: $442.4M for the fiscal year ended Mar 28, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/0000313143-26-000050-index.html
- Employees: 3,009 as of Mar 28, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm
- Shares outstanding: 45,537,511 as of Oct 30, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000152/0000313143-26-000152-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm

## Business

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Mar 28, 2026 | $1.3B | $156.7M | $97.3M | $442.4M |
| Mar 29, 2025 | $1.4B | $221.8M | $167.7M | $436.8M |
| Mar 30, 2024 | $1.3B | $164.9M | $117.6M | $429.8M |
| Apr 1, 2023 | $1.2B | $156.0M | $115.4M | $376.7M |
| Apr 2, 2022 | $993.2M | $80.8M | $43.4M | $340.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/haemonetics-corp.json

## Officers and directors

- Chris Simon, Haemonetics’ CEO. LinkedIn: https://linkedin.com/in/chrissimon1. Source: 8-K filed Aug 6, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000118/ex991-fy27q1earningsrelease.htm
- Christopher Simon, President & CEO. Source: Form 4 filed May 19, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000042/0000313143-26-000042-index.htm
- James D’Arecca, Executive Vice President, Chief Financial Officer. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm
- Frank Chan, EVP, Chief Operating Officer. Source: Form 4 filed May 19, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000047/0000313143-26-000047-index.htm
- Farris Maryanne Maunsell, VP, Chief Accounting Officer. Source: Form 4 filed Jun 8, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000068/0000313143-26-000068-index.htm
- Maryanne E. Farris, Vice President, Chief Accounting Officer. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm
- Michelle L. Basil, EVP and General Counsel. LinkedIn: https://linkedin.com/in/michelle-basil-6711bb5. Source: Form 4 filed May 19, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000048/0000313143-26-000048-index.htm
- Roy Galvin, EVP, Chief Commercial Officer. Source: Form 4 filed May 19, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000044/0000313143-26-000044-index.htm
- Christopher A. Simon, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Claire Pomeroy, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Diane M. Bryant, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Ellen M. Zane, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Lloyd E. Johnson, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Mark W. Kroll, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Martin Madaus, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Michael J. Coyle, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Robert E. Abernathy, director. Source: 8-K filed Jul 28, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Laurie A. Miller, SVP, Human Resources. LinkedIn: https://linkedin.com/in/laurie-miller-6658204. Source: Form 4 filed Jun 8, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000066/0000313143-26-000066-index.htm
- Charles J. Dockendorff, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm
- Claire Pomeroy, M.D., Board member (per proxy). Source: DEF 14A filed Jun 9, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000074/hae-20260605.htm
- Frank W. Chan, Named in proxy. Source: DEF 14A filed Jun 9, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000074/hae-20260605.htm
- James C. D'Arecca, Named in proxy. Source: DEF 14A filed Jun 9, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000074/hae-20260605.htm
- Mark W. Kroll, Ph.D., Board member (per proxy). Source: DEF 14A filed Jun 9, 2026, https://www.sec.gov/Archives/edgar/data/313143/000031314326000074/hae-20260605.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000150/hae-20261105.htm
- Oct 8, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000138/hae-20261008.htm
- Aug 18, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000135/hae-20260818.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000118/hae-20260806.htm
- Jul 28, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm
- Jun 5, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000057/hae-20260605.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000031/hae-20260507.htm
- May 1, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000023/hae-20260427.htm
- Mar 3, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000017/hae-20260303.htm
- Feb 12, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000014/hae-20260212.htm

## Insider trades (Form 4)

- Nov 10, 2025: Mark W. Kroll (Director) bought 1,400 shares, about $98,784. Source: https://www.sec.gov/Archives/edgar/data/313143/000031314325000078/0000313143-25-000078-index.htm

## What management said

- "Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value" Chris Simon, Haemonetics’ CEO (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000150/ex991-fy27q2earningsrelease.htm
- "We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholde" Chris Simon, Haemonetics’ CEO (8-K filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000118/ex991-fy27q1earningsrelease.htm

## Latest filings

- 8-K filed Oct 8, 2026: https://www.sec.gov/Archives/edgar/data/313143/000031314326000138/hae-20261008.htm
- 10-K filed May 20, 2026: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/313143/000031314326000120/hae-20260627.htm
- DEF 14A filed Jun 9, 2026: https://www.sec.gov/Archives/edgar/data/313143/000031314326000074/hae-20260605.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/